Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Celltrion, Inc. (Korean: 주식회사 셀트리온) is a biopharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion. Celltrion's founder, Seo Jung-jin, is the richest person in South Korea. Seo Jung-jin, its founder was awarded the 2021 EY…
History, Art, Regions & Companies
Explore the main themes, entities and connections around Celltrion. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
korea biosimilar inc south distribution founder seo jung-jin europe healthcare co ltd biopharmaceutical remsima products incheon established approved company medicines
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Celltrion | Area served | Worldwide | 1.00 | infobox |
| Celltrion | Founded | 2002; 24 years ago (2002) | 1.00 | infobox |
| Celltrion | Founder | Seo Jung-jin | 1.00 | infobox |
| Celltrion | Headquarters | Yeonsu-gu, Incheon, South Korea | 1.00 | infobox |
| Celltrion | Industry | Biopharmaceutical | 1.00 | infobox |
| Celltrion | Key people | Seo Jung-jin, Chairman Kee Woo-sung, CEO | 1.00 | infobox |
| Celltrion | Net income | ₩1,031,500 million (2025) | 1.00 | infobox |
| Celltrion | Number of employees | 2,995 (2025) | 1.00 | infobox |
| Celltrion | Operating income | ₩1,168,500 million (2025) | 1.00 | infobox |
| Celltrion | Owner | Celltrion Holdings Co., Ltd. (23.03%) Ion Investments B.V. (9.54%) National Pension Service (6.07%) | 1.00 | infobox |
| Celltrion | Products | Remsima™, Truxima™, Herzuma™, Biosimilar Drug | 1.00 | infobox |
| Celltrion | Revenue | ₩4,162,500 million (2025) | 1.00 | infobox |
| Celltrion | Subsidiaries | Celltrion Entertainment | 1.00 | infobox |
| Celltrion | Total assets | ₩22,334,900 million (2025) | 1.00 | infobox |
| Celltrion | Total equity | ₩17,352,500 million (2025) | 1.00 | infobox |
| Celltrion | Traded as | KRX: 068270 | 1.00 | infobox |
| Celltrion | Type | Public | 1.00 | infobox |
| Celltrion | Website | www.celltrion.com/en | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.